Clinical Trials Logo

Filter by:
NCT ID: NCT00955643 Completed - Periodontal Disease Clinical Trials

Periodontal Treatment Associated With Hyperbaric Oxygen Therapy

Start date: March 2002
Phase: N/A
Study type: Interventional

Evaluation of the clinical effect of hyperbaric oxygen therapy (HBOT) adjunctively to scaling and root planing (SRP) in the treatment of severe case of chronic periodontitis.

NCT ID: NCT00955552 Completed - Clinical trials for Osteoarthritis of the Knee

Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee

Artico
Start date: August 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of glucosamine and chondroitin sulfate association in the treatment of patients with osteoarthrosis of the knee.

NCT ID: NCT00954447 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Start date: August 2009
Phase: Phase 3
Study type: Interventional

The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.

NCT ID: NCT00953914 Completed - Clinical trials for Diabetes Complications

Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients

Start date: March 2005
Phase: N/A
Study type: Interventional

The purpose of the study is to determine if pyridostigmine bromide improves heart rate variability of type 2 diabetes mellitus subjects with cardiovascular autonomic neuropathy.

NCT ID: NCT00951405 Completed - Clinical trials for Congenital Bleeding Disorder

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Start date: September 1, 2009
Phase: Phase 2
Study type: Interventional

This trial is conducted in Asia, Europe, Japan and North America. The aim of this clinical trial is to investigate the safety and the efficacy of a prophylactic treatment option with long acting coagulation factor VII (LA-rFVIIa) for haemophilia patients with inhibitors.

NCT ID: NCT00951093 Completed - Morbid Obesity Clinical Trials

Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass

Start date: March 2007
Phase: N/A
Study type: Observational

The hypothesis of this study was that gastric bypass (GBP) ameliorates gastroesophageal reflux disease (GERD) in morbidly obese patients.

NCT ID: NCT00950937 Completed - HIV Infections Clinical Trials

Exercise, Oxidative Stress and HIV

Start date: June 2006
Phase: N/A
Study type: Observational

The purpose of this study is to compare oxidative stress markers and the immunologic characteristics of HIV-infected and non-HIV subjects during a bout of moderate aerobic exercise followed by resistance exercises

NCT ID: NCT00950300 Completed - Breast Cancer Clinical Trials

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Start date: October 16, 2009
Phase: Phase 3
Study type: Interventional

In this open-label multicenter trial, participants with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil, epirubicin, and cyclophosphamide) concurrent with either SC Herceptin or IV Herceptin. After surgery, participants will receive a further 10 cycles of SC or IV Herceptin as per randomization to complete 1 year of treatment. All cycles will be 21 days in length. After the end of study treatment, participants will be followed for safety and efficacy for up to 5 years or until disease recurrence, whichever is earlier.

NCT ID: NCT00949910 Completed - Clinical trials for Non-Small Cell Lung Cancer

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Start date: November 2004
Phase: Phase 4
Study type: Interventional

This study will provide treatment with erlotinib to participants with advanced NSCLC who have received at least one course of standard chemotherapy or radiation therapy, or who are not medically suitable for either. Efficacy and safety will be monitored throughout the study.

NCT ID: NCT00949780 Completed - Clinical trials for Sedation With Chloral Hydrate

Chloral Hydrate to Perform Auditory Brainstem Response (ABR)

Start date: October 2007
Phase: Phase 2
Study type: Interventional

Chloral Hydrate (CH) is a well known drug for sedative and hypnotic purposes used in pediatric and dental procedures owing to the low depressive effect it has over respiratory and cardiac systems. Despite that, the literature reports cases of heart arrhythmia and sudden death in children, especially when using high doses, probably due to accumulation of serum trichloroethanol, an intermediate metabolite resulting from the liver metabolism of the drug. A possible carcinogenic action observed in guinea pigs has also been reported, even though it has not been confirmed in human beings. Among the least severe complications there are paradoxical agitation, nausea, vomiting and excessive sleepiness. CH is the drug of choice to sedate children undergoing Auditory Brainstem Response test (ABR), in which any movement or muscle contraction may generate artifacts that interfere in the analysis. Profound sleep that lasts on average one hour is rapidly induced depending on the used dose, causing no residual sleepiness after this period; however, there is consensus in the literature about the best dose, which may range from 40 to 100 mg/kg. Objective: To assess the efficacy of CH as a sedative agent in performing ABR in children and to systematize its use.